APP and Alzheimer disease: On the other hand, in the ACH2.0 perspective, ACH-based drugs could potentially be effective in prevention of AD, if administered prior to the commencement of the disease, for exactly the same reason they are effective in transgenic AD models: the inactivity of the AβPP-independent iAβ production pathway at this stage.